1. Home
  2. NAUT vs AKBA Comparison

NAUT vs AKBA Comparison

Compare NAUT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nautilus Biotechnolgy Inc.

NAUT

Nautilus Biotechnolgy Inc.

HOLD

Current Price

$2.64

Market Cap

383.5M

Sector

Industrials

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.44

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAUT
AKBA
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.5M
375.0M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
NAUT
AKBA
Price
$2.64
$1.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$4.00
$5.25
AVG Volume (30 Days)
296.9K
2.3M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
16.07
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$992.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$1.14
52 Week High
$4.31
$4.08

Technical Indicators

Market Signals
Indicator
NAUT
AKBA
Relative Strength Index (RSI) 40.70 52.66
Support Level $1.82 $1.31
Resistance Level $3.18 $1.56
Average True Range (ATR) 0.24 0.08
MACD -0.09 -0.00
Stochastic Oscillator 11.56 42.59

Price Performance

Historical Comparison
NAUT
AKBA

About NAUT Nautilus Biotechnolgy Inc.

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: